Leerink Partnrs Brokers Boost Earnings Estimates for TWST

Twist Bioscience Co. (NASDAQ:TWST) – Leerink Partnrs raised their Q1 2025 earnings per share (EPS) estimates for shares of Twist Bioscience in a note issued to investors on Monday, November 18th. Leerink Partnrs analyst P. Souda now expects that the company will post earnings per share of ($0.65) for the quarter, up from their prior forecast of ($0.71). The consensus estimate for Twist Bioscience’s current full-year earnings is ($2.56) per share. Leerink Partnrs also issued estimates for Twist Bioscience’s Q2 2025 earnings at ($0.62) EPS, Q3 2025 earnings at ($0.56) EPS, Q4 2025 earnings at ($0.51) EPS, FY2025 earnings at ($2.34) EPS and FY2026 earnings at ($1.84) EPS.

A number of other research firms have also recently weighed in on TWST. Evercore ISI increased their price objective on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Barclays dropped their price objective on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a research note on Tuesday. Leerink Partners boosted their price objective on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a report on Thursday, October 17th. JPMorgan Chase & Co. raised their target price on Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a report on Monday, August 5th. Finally, Robert W. Baird boosted their price target on shares of Twist Bioscience from $46.00 to $48.00 and gave the stock an “outperform” rating in a research note on Tuesday. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $51.78.

Twist Bioscience Trading Up 1.4 %

Twist Bioscience stock opened at $42.23 on Thursday. The stock has a market cap of $2.51 billion, a P/E ratio of -11.81 and a beta of 1.78. The company has a 50-day moving average price of $43.88 and a 200 day moving average price of $46.12. Twist Bioscience has a 12-month low of $23.07 and a 12-month high of $60.90.

Hedge Funds Weigh In On Twist Bioscience

A number of large investors have recently made changes to their positions in the stock. Thrivent Financial for Lutherans acquired a new stake in Twist Bioscience in the 3rd quarter valued at about $43,992,000. Point72 Asset Management L.P. grew its position in shares of Twist Bioscience by 1,021.8% in the second quarter. Point72 Asset Management L.P. now owns 673,057 shares of the company’s stock valued at $33,168,000 after purchasing an additional 613,057 shares during the last quarter. Fred Alger Management LLC increased its stake in shares of Twist Bioscience by 720.7% during the 2nd quarter. Fred Alger Management LLC now owns 654,877 shares of the company’s stock worth $32,272,000 after purchasing an additional 575,080 shares in the last quarter. State Street Corp increased its stake in shares of Twist Bioscience by 19.9% during the 3rd quarter. State Street Corp now owns 3,167,353 shares of the company’s stock worth $143,101,000 after purchasing an additional 526,028 shares in the last quarter. Finally, Wellington Management Group LLP raised its position in shares of Twist Bioscience by 188.5% during the 3rd quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock worth $36,042,000 after purchasing an additional 521,272 shares during the last quarter.

Insiders Place Their Bets

In related news, CEO Emily M. Leproust sold 1,730 shares of the stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $46.94, for a total transaction of $81,206.20. Following the completion of the transaction, the chief executive officer now directly owns 495,523 shares of the company’s stock, valued at $23,259,849.62. This represents a 0.35 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CAO Robert F. Werner sold 1,448 shares of Twist Bioscience stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total value of $64,580.80. Following the completion of the sale, the chief accounting officer now directly owns 45,620 shares in the company, valued at $2,034,652. This represents a 3.08 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 98,118 shares of company stock valued at $4,391,151. Insiders own 3.92% of the company’s stock.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.